La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Arbutus Biopharma Croissance future
Future contrôle des critères 2/6
Arbutus Biopharma devrait augmenter ses bénéfices et ses revenus de 10.8% et de 34% par an respectivement, tandis que le BPA devrait croître de croître de 14.3% par an.
Informations clés
10.9%
Taux de croissance des bénéfices
14.3%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 29.6% |
Taux de croissance des recettes | 33.9% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 05 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Jul 05Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 9 | -84 | N/A | N/A | 1 |
12/31/2025 | 6 | -73 | N/A | N/A | 5 |
12/31/2024 | 7 | -74 | N/A | N/A | 5 |
6/30/2024 | 10 | -77 | -73 | -73 | N/A |
3/31/2024 | 13 | -74 | -79 | -78 | N/A |
12/31/2023 | 18 | -73 | -87 | -86 | N/A |
9/30/2023 | 22 | -75 | -87 | -86 | N/A |
6/30/2023 | 24 | -73 | -84 | -83 | N/A |
3/31/2023 | 33 | -70 | -84 | -83 | N/A |
12/31/2022 | 39 | -69 | -36 | -35 | N/A |
9/30/2022 | 36 | -69 | -38 | -38 | N/A |
6/30/2022 | 33 | -76 | -36 | -35 | N/A |
3/31/2022 | 21 | -85 | -30 | -29 | N/A |
12/31/2021 | 11 | -88 | -68 | -68 | N/A |
9/30/2021 | 10 | -87 | -64 | -63 | N/A |
6/30/2021 | 8 | -84 | -60 | -59 | N/A |
3/31/2021 | 8 | -79 | -54 | -54 | N/A |
12/31/2020 | 7 | -76 | -52 | -51 | N/A |
9/30/2020 | 6 | -83 | -50 | -50 | N/A |
6/30/2020 | 8 | -147 | -61 | -61 | N/A |
3/31/2020 | 7 | -156 | -70 | -70 | N/A |
12/31/2019 | 6 | -165 | -72 | -71 | N/A |
9/30/2019 | 6 | -158 | -75 | -75 | N/A |
6/30/2019 | 5 | -100 | -65 | -64 | N/A |
3/31/2019 | 5 | -73 | -65 | -64 | N/A |
12/31/2018 | 6 | -67 | -69 | -68 | N/A |
9/30/2018 | 7 | -83 | -62 | -61 | N/A |
6/30/2018 | 12 | -68 | -65 | -64 | N/A |
3/31/2018 | 12 | -86 | N/A | -51 | N/A |
12/31/2017 | 11 | -85 | N/A | -49 | N/A |
9/30/2017 | 8 | -267 | N/A | -53 | N/A |
6/30/2017 | 2 | -275 | N/A | -52 | N/A |
3/31/2017 | 1 | -387 | N/A | -64 | N/A |
12/31/2016 | 1 | -384 | N/A | -58 | N/A |
9/30/2016 | 14 | -171 | N/A | -60 | N/A |
6/30/2016 | 18 | -180 | N/A | -47 | N/A |
3/31/2016 | 21 | -65 | N/A | -48 | N/A |
12/31/2015 | 23 | -63 | N/A | -56 | N/A |
9/30/2015 | 17 | -62 | N/A | -45 | N/A |
6/30/2015 | 17 | -42 | N/A | -49 | N/A |
3/31/2015 | 15 | -33 | N/A | -39 | N/A |
12/31/2014 | 15 | -39 | N/A | -12 | N/A |
9/30/2014 | 18 | -35 | N/A | -3 | N/A |
6/30/2014 | 17 | -33 | N/A | 0 | N/A |
3/31/2014 | 18 | -30 | N/A | 5 | N/A |
12/31/2013 | 15 | -14 | N/A | -7 | N/A |
9/30/2013 | 12 | 26 | N/A | 31 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ABUS devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ABUS devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ABUS devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ABUS ( 34% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ABUS ( 34% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ABUS devrait être élevé dans 3 ans